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Abstract
Background: Elevated liver enzymes are markers of liver steatosis and metabolic syndrome. We
aimed to investigate the association of Mediterranean diet on the relationship between
aminotransferases (i.e., AST, ALT, gGT) and the metabolic syndrome.
Methods: The ATTICA study has randomly enrolled 1514 adult males (18–87 yrs) and 1528
females (18–89 yrs) from the greater area of Athens. Adherence to Mediterranean diet was
assessed through the MedDietScore. According to NCEP III criteria, participants were classified
into those with or without the metabolic syndrome.
Results: Women with metabolic syndrome had higher γGT (p = 0.02) and lower AST/ALT levels
(p = 0.018) than those without, and men with metabolic had a lower AST/ALT ratio (p = 0.01)
compared to those without metabolic syndrome. The AST/ALT ratio was also positively correlated
with MedDietScore (rho = 0.17, p < 0.001), while higher MedDietScore was associated with lower
likelihood of having the metabolic syndrome in a multi-adjusted analysis (OR = 0.34, 95% CI: 0.16–
0.73). Stratified analysis by the level of adherence to the Mediterranean diet, revealed that only in
subjects away or with moderate adherence to the Mediterranean diet, an increase in the AST/ALT
ratio was associated with lower likelihood of having the metabolic syndrome (OR = 0.33, p < 0.05
and OR = 0.34, p < 0.09, respectively); however, when we focused in those with greater adherence
to the Mediterranean diet, AST/ALT ratio was not associated with the presence of the syndrome
(OR = 0.51, p = 0.55). These findings remained similar in both genders, and even when the quantity
of alcohol drinking was taken into account.
Conclusion: Aminotransferases ratio constitutes a marker of the metabolic syndrome among
healthy adults; however, this relationship is moderated when individuals are close to the
Mediterranean dietary pattern.
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Introduction
The metabolic syndrome is a combination of metabolic
disorders, such as dyslipidemia, hypertension, impaired
glucose tolerance, compensatory hyperinsulinemia and
the tendency to develop fat around the abdomen [1]. Peo-
ple with metabolic syndrome are at high risk for athero-
sclerosis and, consequently, cardiovascular disease.
Alanine aminotranferase (ALT), aspartate aminotrans-
ferase (AST) and gamma -glutamyltransferase (γGT) are
common markers of liver injury. Non alcoholic fatty liver
disease (NAFLD) constitutes the most frequent explana-
tion for abnormal liver tests results and accounts for
asymptomatic elevation of aminotransferase levels in up
to 90% of cases. [2,3] It is proposed that NAFLD may be
part of a wider coexistence of features, besides the core set
of disorders which characterize the metabolic syndrome
and liver enzymes-NAFLD associated biomarkers have
indeed been correlated with metabolic syndrome, its com-
ponents and cardiovascular disease. [4-8] Among the dif-
ferent liver enzymes, ALT has been related with hepatic fat
deposition and insulin resistance which plays a major role
in metabolic syndrome. [9] In cases where AST/ALT ratio
has been used instead of ALT, it has been found that this
ratio is also correlated with metabolic syndrome and insu-
lin resistance [10,11] AST/ALT ratio could be useful for
distinguishing the etiology and severity of different liver
damage as a value >2 may indicate advanced alcohol liver
disease and on the other hand, AST/ALT <1 may imply fat
liver accumulation and NAFLD. [12-14] Nevertheless, the
exact role of AST/ALT ratio in assessing metabolic syn-
drome is unclear.
Previous data from the ATTICA and other studies have
shown that Mediterranean diet is related with lower prev-
alence of the metabolic syndrome. [15,16] However, the
underlying mechanisms are not fully understood. Ôhe
effect of this type of diet on liver enzymes and NAFLD is
barely explored, so it is not yet investigated such a possi-
ble mediator for the effect of Mediterranean diet to the
presence of the metabolic syndrome. [17] Therefore, the
goal of the present work was to evaluate whether serum
circulating liver markers, like γ-GT, AST, ALT and AST/ALT
ratio are associated with the presence of the metabolic
syndrome, in a Greek adult population, free from cardio-
vascular disease. Furthermore, we sought to investigate
whether adherence to the Mediterranean diet plays a role
in the relationship of circulating liver markers with meta-
bolic syndrome.
Methods
Participants of the study
The ATTICA study is a health and nutrition survey, which
is being carried out in the province of Attica (including
78% urban and 22% rural areas), where Athens, is a major
metropolis. [18] The sampling was random, multistage
and based on the age-sex distribution of the province of
Attica provided by the National Statistical Service (census
of 2001). The sampling anticipated enrolling only people
without any clinical history of cardiovascular disease or
any other atherosclerotic disease. People who reported
chronic viral hepatitis or other known cause of chronic
liver disease were excluded from the study. Participants
did not have cold or flu, acute respiratory infection, dental
problems or any type of surgery during the past weeks.
From May 2001 to December 2002, 4056 inhabitants
from the above area were randomly selected and of them,
3042 agreed to participate (75% participation rate); 1514
males (18–87 years) and 1528 females (18–89 years). The
selected sample can be considered as representative since
there were only minor, insignificant, differences in sex
and age distribution between the study- and the target
population.
All participants were interviewed by trained personnel
who used a standard questionnaire that evaluated lifestyle
habits and various socio-demographic, clinical and bio-
logical characteristics. The study was approved by the Eth-
ics Committee of our Institution and was carried in
accordance with the declaration of Helsinki (1989) of the
World Medical Association.
Dietary assessment
Consumption of non-refined cereals and products, vege-
tables, legumes, fruits, olive oil, dairy products, fish,
pulses, nuts, potatoes, eggs, sweets, poultry, red meat and
meat products were measured as an average per week dur-
ing the past year through a validated food-frequency ques-
tionnaire (the EPIC-Greek) [19]. The frequency of
consumption was then quantified approximately in terms
of the number of times a month a food was consumed.
Alcohol consumption was measured by daily ethanol
intake, in wineglasses (100 ml and 12% ethanol concen-
tration). The Mediterranean dietary pattern [20] consists
of: (a) daily consumption: of non refined cereals and
products (whole grain bread, pasta, brown rice, etc), veg-
etables (2 – 3 servings/day), fruits (6 servings/day), olive
oil (as the main added lipid) and dairy products (1 – 2
servings/day), (b) weekly consumption: of fish (4–5 serv-
ings/week), poultry (3 – 4 servings/week), olives, pulses,
and nuts (3 servings/week), potatoes, eggs and sweets (3
– 4 servings/week) and monthly consumption: of red
meat and meat products (4 – 5 servings/month). It is,
also, characterized by moderate consumption of wine (1
– 2 wineglasses/day) and high monounsaturated: satu-
rated fat ratio (> 2). To evaluate the level of adherence to
the Mediterranean dietary pattern a special diet score was
used, the MedDietScore [21]; the score has been found
reliable, repeatable and valid, in previous works [22]. In
particular, for the consumption of food items that are
close to this dietary pattern we assigned score 0 for rare or
no consumption, 1 for 1 to 4 times/month, 2 for 5 to 8Nutrition & Metabolism 2009, 6:30 http://www.nutritionandmetabolism.com/content/6/1/30
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times, 3 for 9 to 12 times/month, 4 for 13 to 18 times/
month and 5 for almost daily consumption. On the other
hand, for the consumption of foods that are away from
this traditional diet, like meat and meat products, we
assigned the opposite scores (i.e. 0 for almost daily con-
sumption to 5 for rare or no consumption). For alcohol,
we assigned score 5 for consumption of less than 3 wine-
glasses/day and, progressively, score 0 for consumption of
more than 7 wineglasses/day. Thus, the range of the diet
score is between 0 – 55. Higher values of the suggested
dietary score indicate greater adherence to the traditional
Mediterranean diet.
Biochemical measurements
The blood samples were collected from the antecubital
vein between 8 to 10 a.m., in a sitting position after 12
hours of fasting and avoiding of alcohol. Serum was har-
vested immediately after admission. The biochemical
evaluation was carried out in the same laboratory that fol-
lowed the criteria of the World Health Organization Lipid
Reference Laboratories. ALT, AST and γ-GT but also blood
lipids were measured by using chromatographic enzymic
method in an automatic analyzer (RA-1000, Dade
Behring, Marburg, Germany). The intra-assay and inter-
assay coefficient of variation was <5% for ALT, AST and γ-
GT. An internal quality control was in place for assessing
the validity of cholesterol, triglyceride and HDL methods.
The intra and inter-assay coefficients of variation of cho-
lesterol levels did not exceed 9%, triglycerides 4% and
HDL 4%. Blood glucose levels were measured with a Beck-
man Glucose Analyzer. The intra-assay coefficient of vari-
ation was 9% and the limit of detection was 3 μU/mL.
Demographic, clinical and lifestyle characteristics
The study's questionnaire also included demographic
characteristics like age, gender, and education level in
years of school. Information about smoking habits was
collected using a standardized questionnaire developed
for the Study. Current smokers were defined as those who
smoked at least 1 cigarette per day, former smokers were
defined as those who had stopped smoking more than 1
year previously and the rest were defined as non-current
smokers. For the ascertainment of physical activity status
we used the International Physical Activity Questionnaire
(IPAQ), as an index of weekly energy expenditure using
frequency (times per week), duration (in minutes per
time) and intensity of sports or other habits related phys-
ical activity (in MET/minutes) [23]. Participants who did
not report any physical activities were defined as seden-
tary.
Body mass index (BMI) was calculated as weight (in kilo-
grams) divided by height (in meters) squared. Based on
the World Health Organization classification, overweight
was defined as BMI between 25 and 29.9 kg/m2, and obes-
ity was defined as BMI 30 kg/m2. [24] We also measured
waist circumference (in centimetres) in the middle
between the 12th rib and iliac crest. Arterial blood pressure
was measured three times at the end of the physical exam-
ination with subject in sitting position. Participants
whose average blood pressure levels were greater or equal
to 140/90 mmHg or were under antihypertensive medica-
tion were classified as hypertensive subjects [25]. Hyperc-
holesterolemia was defined as total serum cholesterol
levels greater than 200 mg/dL or the use of lipid-lowering
agents and diabetes mellitus as a blood sugar > 125 mg/
dL or the use of antidiabetic medication [26].
Definition of the metabolic syndrome
Participants were classified as having the metabolic syn-
drome or not, according to the definition provided by the
National Cholesterol Education Panel -NCEP ATP III,
consequently, if 3 or more of the following metabolic
components are present: waist circumference ≥ 102 cm for
males or ≥ 88 cm for females; triglyceride level ≥ 150 mg/
dl; HDL cholesterol level <40 mg/dL for males or <50 mg/
dL for females; blood pressure ≥ 130/85 mmHg; fasting
blood glucose ≥ 100 mg/dL. [27]
Statistical analysis
Continuous variables are presented as mean values ±
standard deviation, while categorical variables are pre-
sented as absolute number and frequencies. Associations
between categorical variables were tested by the use of
contingency tables and the calculation of chi-squared test.
Differences between groups of study in normally distrib-
uted continuous variables were evaluated by the calcula-
tion of Student's t-test, while the Mann-Whitney test was
used for the skewed variables. Correlations between bio-
chemical markers and other continuous variables were
tested using the Spearman or the Pearson's correlation
coefficients. Binary and ordinal logistic regression analysis
was used to evaluate the effect of selected aminotran-
ferases levels on the likelihood of having the metabolic
syndrome, as well as the number of metabolic disorders.
The Wald statistic was used to hierarchy the effect of ami-
notranferases on the number of metabolic disorders in the
ordinal logistic regression analyses. Multi-adjusted analy-
sis has taken into consideration variables as age, sex, BMI,
smoking habits, physical activity status and MedDiet-
Score. Hosmer-Lemeshow statistic was used to evaluate
models; goodness-of-fit. All reported p-values are based
on two-sided tests and compared to a significance level of
5%. SPSS 14.0 software (SPSS Inc. 2002, Chicago, Illinois,
USA) was used for all the statistical calculations.
Results
Participants' characteristics, liver enzymes and the 
metabolic syndrome
AST levels were higher in males compared to females (27
± 12 vs. 24 ± 11 IU/L, p = 0.001); similarly ALT levels were
higher in males (24 ± 14 vs. 18 ± 10 IU/L, p = 0.001), asNutrition & Metabolism 2009, 6:30 http://www.nutritionandmetabolism.com/content/6/1/30
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well as γ-GT levels (males: 27 ± 14 vs. females: 18 ± 13 IU/
L, p = 0.001). The AST/ALT ratio was lower in males (1.2
± 0.4 vs. 1.4 ± 0.6, p = 0.02). Moreover, ALT, AST and γ-GT
levels were positively correlated with BMI (r = 0.14, p =
0.001, and r = 0.29, p = 0.001 and respectively r = 0.35, p
= 0.001), while no associations were found regarding age,
smoking habits and physical activity status of the partici-
pants.
Table 1 illustrates various characteristics of the partici-
pants according to the metabolic syndrome status. Both
males and females with metabolic syndrome were more
likely to be older, with higher BMI, lower MedDietScore
and a greater prevalence of hypertension, hypercholester-
olemia and diabetes. In males, γ-GT, AST and ALT concen-
trations did not differ statistically between the two groups
and only a lower AST/ALT ratio was found in males with
metabolic syndrome. In females, γ-GT was higher and
AST/ALT ratio lower in those with metabolic syndrome,
AST levels were similar between the two groups and ALT
did not differ statistically.
Unadjusted analysis revealed that 1 unit increase in AST/
ALT ratio was associated with 0.37-times (95%CI 0.16–
0.84) lower likelihood of having the syndrome in males
and with 0.48-times lower likelihood in females (95%CI
0.28–0.86). Greater adherence to the Mediterranean diet
was associated with lower likelihood of having the meta-
bolic syndrome (OR per 1 unit increase in diet score in
males = 0.97, 95%CI 0.95–0.99, and OR per 1 unit
increase in females = 0.90, 95%CI 0.88–0.92). Further-
more, the number of metabolic components of the partic-
ipants was positively correlated with γ-GT (rho = 0.39, p <
0.001), ALT (rho = 0.22, p < 0.001) concentrations and
inversely correlated with AST/ALT ratio (rho = -0.20, p <
0.001). Further trend analysis, after adjusting for age, sex,
Table 1: Demographic, lifestyle, and clinical characteristics of males and females with and without the metabolic syndrome
Males, n = 1514 Metabolic syndrome No metabolic syndrome p
Subjects, n 379 1135
Age, years 50 ± 11 44 ± 13 < 0.001
Physical inactivity (n), % (136) 36 (488)43 0.002
Current smoking (n), % (174) 46 (533) 47 0.81
Med Diet score (0–55) 23.4 ± 6.1 24.5 ± 5.5 0.01
Hypertension (n), % (242) 64 (306) 27 < 0.001
Hypercholesterolemia (n), % (216) 57 (420) 37 < 0.001
Diabetes (n), % (72) 19 (45) 4<  0 . 0 0 1
Overweight (n), % (208) 56 (533) 47 < 0.001
Obesity (n), % (167) 44 (136) 12 < 0.001
Body mass index (kg/m2) 29.8 ± 0.2 26.5 ± 0.1 < 0.001
γ-GT (IU/L) 28 ± 12 26 ± 14 0.24
AST (IU/L) 27 ± 14 27 ± 11 0.98
ALT (IU/L) 26 ± 17 23 ± 12 0.25
AST/ALT ratio 1.11 ± 0.3 1,28 ± 0,48 0.01
Females, n = 1528 Metabolic syndrome No metabolic syndrome p
Subjects, n 228 1300
Age, years 53 ± 14 43 ± 14 < 0.001
Physical inactivity (n), % (62) 27 (520) 40 < 0.001
Current smoking (n), % (78) 34 (520) 40 0.07
Med Diet score (0–55) 24 ± 6.8 28.2 ± 7.2 < 0.001
Hypertension (n), % (128) 56 (234) 18 < 0.001
Hypercholesterolemia (n), % (114) 50 (442) 34 < 0.001
Diabetes (n), % (52) 23 (39) 3<  0 . 0 0 1
Overweight (n), % (87) 38 (377) 29 < 0.001
Obesity (n), % (105) 46 (130) 10 < 0.001
Body mass index (kg/m2) 29.8 ± 4.9 24.5 ± 4.3 < 0.001
γ-GT (IU/L) 21 ± 12 17 ± 13 0.02
AST (IU/L) 23 ± 9 23 ± 11 0.76
ALT (IU/L) 20 ± 12 18 ± 10 0.18
AST/ALT ratio 1.26 ± 0.3 1.44 ± 0.6 0.018
Continuous variables are presented as mean values ± standard deviation, while categorical variables are presented as absolute number and 
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physical activity and smoking habits revealed that γ-GT
(Wald test = 16.79, p < 0.001), followed by ALT (Wald test
= 16.27, p < 0.001), AST/ALT ratio (Wald test = 11.82, p =
0.001), were positively associated with the number of
metabolic components of the studied sample, while AST
(Wald test = 2.41, p = 0.12) showed no significant effect.
No gender interactions were observed.
A multi-adjusted analysis, taking into consideration age,
sex, BMI, smoking habits, physical activity status and
MedDietScore, revealed that a higher AST/ALT ratio was
associated with lower likelihood of having the metabolic
syndrome (OR = 0.34, 95%CI 0.16–0.73). Additionally,
when AST/ALT ratio was categorized in quartiles (males: <
0.93, 0.93–1.16, 1.16–1.43 and >1.43 and females: <1.06,
1.06–1.31, 1.31–1.64 and >1.64), only participants
belonging in the highest quartile of AST/ALT ratio were
less likely to have the metabolic syndrome, compared to
those in the lowest quartile (males: OR = 0.22, 95%CI
0.06–0.80 and females: OR = 0.34, 95%CI 0.13–0.91).
No significant associations were observed when AST, ALT
markers were tested separately for the presence of the syn-
drome (p = 0.29 and p = 0.30, respectively). Furthermore,
no significant interaction effect was observed between
aminotransferases levels and gender, on the investigated
outcome (p = 0.87). Thus, it was decided to perform a
pooled analysis with genders combined, in order to
increase the statistical power of the analyses.
Liver enzymes and Mediterranean diet score
Table 2 demonstrates the associations of liver enzymes
and other characteristics of the participants with the Med-
DietScore categories. ALT, AST and γ-GT were inversely
associated with the level of adherence to the Mediterra-
nean diet in females, but not in males.
Although unadjusted aminotransferase ratio did not differ
between lower and higher tertile of MedDietScore, further
data analysis in the whole population, after adjustment
for BMI and alcohol drinking, revealed a positive correla-
tion with AST/ALT ratio (rho = 0.17, p < 0.001) and an
inverse correlation with AST (rho = -0.11, p = 0.03) and
ALT levels (rho = -0.22, p < 0.001). Moreover, a modified
version of the MedDietScore without alcohol intake was
also positively correlated with AST/ALT ratio (rho = 0.17,
p < 0.001), while it was inversely correlated with AST (rho
= -0.11, p = 0.03) and ALT levels (rho = -0.22, p < 0.001).
The previous findings suggest that greater adherence to
the Mediterranean dietary prototype is associated with
reduced aminotranferases levels, and lower ALT concen-
trations relatively to AST.
Liver enzymes, Mediterranean diet and the metabolic 
syndrome
However, a highly significant interaction was observed
between AST/ALT ratio and MedDietScore (p < 0.001). In
Figure 1, the crude effect of Mediterranean diet in the asso-
ciation of AST/ALT ratio with metabolic syndrome is illus-
trated.
Thus, we stratified our analysis by tertile of the diet score
(i.e., lower tertile characterizes people away from this tra-
ditional dietary pattern, middle and highest tertiles which
describe people with moderate and good adherence to the
Mediterranean diet). In Table 3 the results from the logis-
tic regression models that evaluated the association
between liver enzymes and presence of metabolic syn-
drome, by the level of adherence to the Mediterranean
diet, are presented. Multi-adjusted analysis showed that
among people in the lowest and middle tertiles of the diet
score, higher values of AST/ALT ratio indicate a lower like-
lihood of having the metabolic syndrome (p = 0.05, and p
= 0.09, respectively), after adjusting for age, sex, body
mass index, physical activity status, and smoking habits of
the participants. Ïn the other hand, in people in the high-
est tertile of the diet score, the previous relationship was
not significant (p = 0.51). The aforementioned relation-
ships remained similar even when the quantity of alcohol
drinking was taken into account.
Moreover, no significant associations were observed when
AST, ALT and γ-GT were independently tested against the
presence of the metabolic syndrome in a stratified by diet
pattern analysis.
Discussion
Studying a community-based representative sample of
adult males and females without any clinical evidence of
cardiovascular or other chronic disease, we observed that
the metabolic syndrome was related with a lower AST/ALT
ratio. However, the most interesting finding is that the lat-
ter relationship was altered when people were stratified by
the level of adherence to the traditional Mediterranean
diet. Particularly, AST/ALT ratio constitutes a marker of
the metabolic syndrome only among people that report
moderate to low adherence to the Mediterranean diet,
irrespectively of the quantities of alcoholic beverages
drinking and to the best of our knowledge, this is the first
study to point out such a thing. Although it is known that
a high AST/ALT ratio may be indicative of severe liver
damage from alcohol, it is not the case in our study as the
ratio of aminotransferases is not a combined with ele-
vated liver enzymes but the mean aminotransferase levels
both in people with or without metabolic syndrome were
around 25 IU/L [13]. Moreover, only AST/ALT ratio and
not AST, ALT or γ-GT, was a marker of the syndrome when
dietary habits of people were taken into account, denoting
that aminotransferases concentrations should be consid-
ered together when evaluating the development of the
metabolic syndrome. Additionally, in our study, both
men and women in the higher quartile of the AST/ALT
ratio, where ALT is considerably lower than AST (or ASTNutrition & Metabolism 2009, 6:30 http://www.nutritionandmetabolism.com/content/6/1/30
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considerably higher than ALT), have less likelihood to
have the metabolic syndrome. Why AST behaves differ-
ently than ALT so the ratio becomes important is not clar-
ified; nevertheless, there are some physiological
differences that may explain it. ALT has low concentra-
tions in skeletal muscle and kidneys, so it is more specific
for liver damage than AST that is diffusely represented in
the heart, skeletal muscle, kidneys, brain and red blood
cells. ALT and AST both require pyridoxal-5'-phosphate
(vitamin B6) in order to carry out the reaction of transfer
of α-amino groups from aspartate and alanine to the α-
keto group of ketoglutaric acid but pyridoxal-5'-phos-
phate affects more ALT. Finally, from observational stud-
ies ALT seems to correlate more with insulin resistance but
the nature of this connection need to be elucidated
[28,29]. The associations of aminotransferases levels with
the metabolic syndrome or its constituents have already
been reported [30,31]. Particularly, insulin resistance
study show that liver enzymes may predict metabolic syn-
drome and additionally, that not only ALT but ami-
notransferase ratio also may be used as a marker for
metabolic syndrome [11]. Liver enzymes and the related
pathology of NAFLD are associated with metabolic syn-
drome through many metabolic disorders like overweight
and obesity, dyslipidemia, diabetes and hypertension,
while insulin resistance is now considered the main link
between metabolic disturbances and elevated liver
enzymes [30-33]. Nevertheless, our study has revealed an
association of metabolic syndrome only with AST/ALT
ratio and not also with specific liver enzymes, as the
abovementioned studies. Regarding γGT, although it was
not correlated with metabolic syndrome as a biniary
entity, a trend analysis has shown that it is related with the
number of metabolic components and this is in agree-
Table 2: Demographic, lifestyle, and clinical characteristics of males and females by tertile of Mediterranean diet score
Mediterranean Diet score
Males, n = 1514 Low Moderate High p
Subjects, n 767 587 160
Age, years 53 ± 12 40 ± 8 29 ± 9 < 0.001
Physical inactivity (n), % (314) 41 (235) 40 (80) 50 0.059
Current smoking (n), % (330)43 (299)51 (80)50 0.005
Metabolic syndrome (n), % 36 16 8 <0.001
Hypertension (n), % (368)48 (164) 28 (19)12 < 0.001
Hypercholesterolemia (n), % (360)47 (246)42 (29)18 < 0.001
Diabetes (n), % (100)13 (17)3 (2)1<  0 . 0 0 1
Overweight (n), % (409) 53 (358) 61 (27) 24 < 0.001
Obesity (n), % (272) 36 (28) 5 (1) 1<  0 . 0 0 1
Body mass index (kg/m2) 2 9  ±  42 6  ±  22 3  ±  2 <  0 . 0 0 1
γ – GT (IU/L) 27 ± 14 27 ± 9 19 ± 7 0.059
AST (IU/L) 27 ± 13 27 ± 9 25 ± 12 0.74
ALT (IU/L) 24 ± 14 25 ± 12 21 ± 13 0.45
AST/ALT ratio 1.28 ± 0.45 1.17 ± 0.43 1.33 ± 0.46 0.19
Females Low Moderate High p
Subjects, n 246 428 854
Age, years 60 ± 13 53 ± 10 36 ± 10 < 0.001
Physical inactivity (n), % (79)32 (150)35 (359)42 0.08
Current smoking (n), % (61)25 (163)38 (376)44 < 0.001
Metabolic syndrome (n), % 38 24 4 <0.001
Hypertension, (n), % (125)51 (154)36 (77)9<  0 . 0 0 1
Hypercholesterolemia (n),% (130)53 (210) 49 (25)3<  0 . 0 0 1
Diabetes (n), % (44)18 (38)9 (8) 1<  0 . 0 0 1
Overweight (n), % (84)34 (247) 58 (131) 15 < 0.001
Obesity (n), % (139) 57 (89) 21 (8) 1<  0 . 0 0 1
Body mass index (kg/m2) 3 1  ±  52 7  ±  32 2  ±  2 <  0 . 0 0 1
γ – GT (IU/L) 20 ± 10 20 ± 18 16 ± 8 0.005
AST (IU/L) 24 ± 9 25 ± 13 22 ± 9 0.01
ALT (IU/L) 19 ± 8 20 ± 14 16 ± 8 0.001
AST/ALT ratio 1.31 ± 0.45 1.39 ± 0.71 1.44 ± 0.53 0.29
Continuous variables are presented as mean values ± standard deviation, while categorical variables are presented as absolute number and 
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ment with previous studies [8,31]. The majority of preced-
ing related studies found no relationship between AST
and metabolic disorders. However, most of these studies
have positively correlated ALT with metabolic syndrome;
on the other side, in our study, men had considerably low
levels of ALT (below the cut-off of 30 IU/L for men) in
both groups -those with and those without metabolic syn-
drome [34,35]. In women, the insignificant difference of
ALT levels between those with and without the metabolic
syndrome may be partially explained by the vast distribu-
tion of ALT. Moreover, because of the good level of adher-
ence to the Mediterranean diet of the studied women and
the protective effect of this diet to various metabolic
abnormalities (i.e., hypertension, dyslipidemia, diabe-
tes), one can speculate that the burden of the metabolic
syndrome in our female sample has a more "benign" pro-
file compared with other populations.
Indeed, the favourable effect of Mediterranean diet to the
metabolic syndrome has been demonstrated by a number
of studies, including ATTICA [15,16,36]. However, it is not
lucid if Mediterranean diet could have as well, a beneficial
role to -metabolic syndrome related- liver fat accumulation
and relative biomarkers. It is well-known that by managing
obesity, hypertriglyceridemia, diabetes mellitus and by
moderating alcohol consumption, liver fat may be pre-
vented or minimized. Interventions like drugs, diet and
exercise, that reduce insulin resistance, may decrease the
amount of fat in the liver and normalize aminotransferase
levels [37-39]. As Mediterranean diet is related with less
insulin resistance, one can assume that such a diet could
improve liver fat and enzymes [40]. Our study has estab-
lished a relationship between Mediterranean diet and AST/
ALT ratio, apart from alcohol consumption and other
potential confounders but further enquiry will show if
insulin resistance is the basic mediator of this relation. The
reason why AST elevation occurs independently than ALT
elevation when someone has a great adherence to the Med-
iterranean diet is not clear but maybe it is due to the above-
mentioned differences of aminotransferase functions [28].
Furthermore, additional investigation is needed in order to
comprehend how Mediterranean diet affects the relation of
aminotransferase ratio with metabolic syndrome. A
number of underlying mechanisms may interpret the phe-
nomenon of the dissociation of the abovementioned
parameters. It is already mentioned that ALT and AST/ALT
are markers closely related to pathology of NAFLD, mean-
ing with liver fat storage [9]. Adherence to Mediterranean
diet may well be capable of protecting from building up
more liver fat, even in people with metabolic syndrome or
when the probability of having the metabolic syndrome
AST/ALT ratio and the metabolic syndrome, by the level of adherence to the Mediterranean diet Figure 1
AST/ALT ratio and the metabolic syndrome, by the level of adherence to the Mediterranean diet.Nutrition & Metabolism 2009, 6:30 http://www.nutritionandmetabolism.com/content/6/1/30
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increases. It is possible, that this type of diet reduces the
effect on the liver, of cytokines and adipokines secreted
from the extra adipose tissue. These mediators could affect
the transcriptional factors peroxisome proliferator-acti-
vated receptors (PPARs) and the transcription factor sterol
regulatory element binding protein-1c (SREBP-1c) of hepa-
tocytes, meaning the regulators of mitochondrial fatty oxi-
dation and liver fat synthesis [41]. Furthermore, ALT and
AST/ALT are markers of insulin resistance and "ATTICA"
and other studies have already shown that Mediterranean
diet is associated with lower levels of insulin resistance and
this can be true also in people with metabolic syndrome
[36,40]. Moreover, hypoadiponectinemia which character-
izes metabolic syndrome and its components and seems to
correlate also with NAFLD, may be altered by a Mediterra-
nean diet. In fact, there are indications that levels of adi-
ponectin are related with this type of diet. [42]
On the other hand, Mediterranean diet could minimize
the contribution of hepatic inflammation secondary to
liver steatosis, to the low-grade inflammation associated
with the metabolic syndrome, by reducing, for example,
the hepatic production of tumor necrosis factor-α, which
triggers the production of other cytokines [43]. By turning
down the inflammatory and oxidative processes, Mediter-
ranean diet may also lessen the -derived from liver lipid
storage- hepatic insulin resistance and the raise of endog-
enous glucose production, which in turn may accompany
metabolic syndrome. Moreover, specific insulin pathway
signalling events are altered in the adipose tissue of
patients with NASH compared with non-progressive
forms of NAFLD [44]. So, in case of a great adherence to
Mediterranean diet, other factors apart from liver fat stor-
age must be recognized as responsible for metabolic syn-
drome.
The possible advantageous quality of Mediterranean diet
to AST/ALT ratio and NAFLD should be further investi-
gated by intervention studies. Additionally, the underly-
ing mechanisms by which this type of diet modifies the
relationship of aminotransferases ratio with metabolic
syndrome need to be elucidated.
Limitations
This is a cross-sectional study, so it could not establish
causal relationships, but only states hypotheses about the
link between liver enzymes and aminotransferase ratio
with metabolic syndrome and Mediterranean diet. In dis-
cussion, elevated liver enzymes and low AST/ALT ratio
were utilized as an estimate of liver fat accumulation,
assuming that most cases are markers for NAFLD. By
excluding people with HBsAg+ or anti-HCV, this estima-
tion is even more accurate and this is another limitation
of our study, that participants did not underwent these
measures. Although NAFLD is ideally diagnosed by liver
biopsy, histological and ultrasonographic studies of
patients referred for unexplained aminotransferase eleva-
tions indicate that fatty infiltration of the liver is the cause
in 90% of cases and on top, the use of liver enzymes as
NAFLD markers is a common methodology in epidemio-
logical cross – sectional surveys, and therefore, our results
are comparable. [5,11] Although AST/ALT ratio is
inversely linked with liver fat, in a small percentage of
asymptomatic subjects, it is also correlated with more
severe liver damage and fibrosis, so, the true cause of liver
enzyme elevations and the significance of aminotrans-
ferase ratio, in the study participants cannot be deter-
mined with certainty. Nevertheless, in our study the mean
AST/ALT ratio was <2 for people with but also without
metabolic syndrome, while severe liver damage (from
alcohol) is related with values >2 [13].
Conclusion
Adherence to the Mediterranean diet is positively corre-
lated with AST/ALT ratio and should be further examined
for its favorable impact to non alcoholic fat liver disease.
Table 3: Results from logistic regression analyses that evaluated the role of liver enzymes on the presence of the metabolic syndrome, 
by the level of adherence to the Mediterranean diet.
Away from the Mediterranean diet (n = 1013) Odds ratio 95% confidence interval
AST/ALT ratio (per 0.1 unit) 0.89 0.80–1.00
AST (per 1 IU/L) 0.93 0.88–0.99
ALT (per 1 IU/L) 1.01 0.95–1.07
γ-GT (per 1 IU/L) 0.99 0.95–1.03
Moderate adherence to the Mediterranean diet (n = 1015)
AST/ALT ratio (per 0.1 unit) 0.90 0.78–1.01
AST (per 1 IU/L) 0.96 0.90–1.03
ALT (per 1 IU/L) 0.99 0.92–1.07
γ-GT (per 1 IU/L) 1.02 0.96–1.07
Close to the Mediterranean diet (n = 1014)
AST/ALT ratio (per 0.1 unit) 0.93 0.76–1.13
AST (per 1 IU/L) 0.93 0.76–1.15
ALT (per 1 IU/L) 1.01 0.83–1.22
γ-GT (per 1 IU/L) 1.19 0.99–1.33
All models were also adjusted for age, gender, physical activity status, smoking and body mass index of the participants.Nutrition & Metabolism 2009, 6:30 http://www.nutritionandmetabolism.com/content/6/1/30
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Furthermore, this type of diet modifies the relationship of
the liver enzymes ratio with metabolic syndrome; hence
in people with a great adherence in Mediterranean diet,
alterations in liver enzymes do not affect the likelihood of
having metabolic syndrome and vice versa. Our findings
pose the need for further investigation on whether Medi-
terranean diet may have a positive effect in liver biochem-
istry and liver fat accumulation by moderating metabolic
syndrome related mechanisms or its beneficial role to
metabolic syndrome could partially be explained by its
consequences to liver fat and associated biomarkers.
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